Scott Gettinger, MD
Naiyer A. Rizvi, MD
The phase I CheckMate 012 study examined the effects of nivolumab (Opdivo) monotherapy and nivolumab combined with platinum-based doublets as first-line treatments in patients with advanced non–small cell lung cancer (NSCLC). Encouraging...!-->!-->!-->!-->
There is no question that immune checkpoint inhibitors have a role in untreated advanced lung cancer. How they will be integrated into the upfront setting and which patients are likely to benefit are areas of active research.— Karen Kelly, MD
For the majority of...!-->!-->
[T]he Initiative’s stakeholder survey and workshop are good first steps toward identifying major inefficiencies and potential solutions for alleviating regulatory and administrative burdens on cancer clinical trials.— Julie M. Vose, MD, MBA, FASCO
As reported in the...!-->!-->
Our ultimate success will be defined over the coming years, when we’ve produced transformative new medicines that can be delivered to patients more quickly and at a lower cost than the current paradigm.— Ronald A. DePinho, MD
For several years now, the American...!-->!-->
The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1
Among the patients studied,...
Benjamin L. Judson, MD
“This (adverse cardiac effects of chemotherapy) is a difficult problem to address because the side effects of chemotherapy in terms of its impact on the heart show up many years, sometimes decades, later. So that makes it harder to study and treat. It’s a real...!-->!-->
We concluded that the main specimen margin is significantly associated with local recurrence and is the strongest predictor of recurrence compared to the tumor bed frozen margins and the final operative margin.— Marisa R. Buchakjian, MD, PhD
Perhaps margins are not necessarily a reflection of surgical adequacy, like we use them, but more a reflection of the biology of the disease.— Allen Cheng, MD, DDS
The study findings by Dr. Buchakjian and colleagues suggest it may be time to revisit the significance of ...!-->!-->
Routine surveillance scans are not indicated [for patients with large cell lymphomas]. They are expensive, potentially toxic, and anxiety-provoking. They also have false-positive results, increase cancer risk, and, importantly, do not impact patient outcomes.!-->!-->— Bruce D....
Attendees at the 2016 Pan Pacific Lymphoma Conference held July 18–22 in Koloa, Hawaii, got a peek at early data for a number of novel agents in the treatment of various lymphoma subtypes. The ASCO Post captured these findings.
Denintuzumab Mafodotin in Diffuse Large B-Cell Lymphoma
Charles Mullighan, MBBS (Hons), MD
The American Society of Hematology (ASH) will present the 2016 William Dameshek Prize to Charles Mullighan, MBBS (Hons), MD, of St. Jude Children’s Research Hospital, for his leadership in defining the landscape of genetic alterations of acute lymphocytic ...!-->!-->
This analysis, although exploratory, suggests that patients with human epidermal growth factor receptor 2–positive advanced breast cancer having tumors with PIK3CA mutations, PTEN loss, or hyperactive PI3K pathway could derive [progression-free survival] benefit from everolimus. ...!-->!-->
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for the use of ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The application, which...
Ronald de Wit, MD
The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid) or docetaxel/prednisone, in the phase III Mainsail trial. de...!-->!-->
A collaborative Cleveland Clinic–Mayo Clinic team of researchers has shown for the first time that patients with advanced prostate cancer are more likely to die earlier of their disease if they carry a specific testosterone-related genetic abnormality. The findings, published by Hearn et al in The...
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening.1 In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...
As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines for colorectal cancer screening1 from 2008 and has now included seven acceptable strategies, including direct-visualization modalities (ie, endoscopy and computed tomography...
Patients with metastatic NSCLC are now surviving much longer than they did 10 years ago, but these changes have not been reflected in stage III patients.— Rafael Santana-Davila, MD
Clinicians face a number of questions in evaluating and treating patients with stage IIIA ...!-->!-->
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the first-line treatment of patients with advanced non–small cell lung cancer...
Steven Narod, MD, FRCPC, PhD (hon), FRSC
The Basser Center for BRCA at Penn’s Abramson Cancer Center has announced the recipient of the 2016 Basser Global Prize is cancer geneticist Steven Narod, MD, FRCPC, PhD (hon), FRSC, Director of the Familial Breast Cancer Research Unit and a senior...!-->!-->
We still don’t have a single, validated formula that can determine who needs postmastectomy radiotherapy, but we hope that the research evidence summarized in this guideline update will help doctors and patients make more informed decisions.— Stephen B. Edge, MD
Julie E. Bauman, MD, MPH
Julie E. Bauman, MD, MPH, a head and neck cancer specialist and physician-scientist, has been named Professor of Medicine and the new Chief of the Division of Hematology and Oncology at the University of Arizona (UA) College of Medicine–Tucson, as well as Associate ...!-->!-->
Maha H. Hussain, MD
Maha H. Hussain, MD, has joined the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as the Associate Director for Clinical Sciences Research. Dr. Hussain will also serve as Co-Director of the Lurie Cancer Center’s Genitourinary Oncology Program,...!-->!-->
Veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone, specifically in triple-negative breast cancer.— Hope S. Rugo, MD, and colleagues
As reported by Hope S. Rugo, MD, and John W. Park,...!-->!-->
While identifying appropriate agents for testing in larger randomized trials, the pressure to generate data that can lead to drug approval may make it more difficult to explore alternative regimens in the hope of improving efficacy and/or reducing toxicity and could result in...!-->!-->
The U.S. Food and Drug Administration (FDA) announced on September 15 that it has taken action against 55 tobacco retailers by issuing the first warning letters for selling newly regulated tobacco products—such as e-cigarettes, e-liquids, and cigars—to minors. These actions come about a month after ...
Sustainability down the road is a primary goal. Our success depends on creating long-term relationships with government officials and the people in the communities we serve.— Robert D. Hilgers, MD
Cervical cancer incidence and mortality rates—perhaps more than any...!-->!-->
I am a family physician and also provide palliative care. What I usually say to my seriously ill patients is, “We are in a situation where there is some uncertainty. I’m hoping for the best and that you’ll beat the odds. Do you want to know more?...!-->!-->— Ronald M. Epstein, MD
The American Association for Cancer Research (AACR) and its Chief Executive Officer, Margaret Foti, PhD, MD (hc), were honored with the PHL Life Sciences Ultimate Solution Award for their significant contributions to and impact on the field of cancer research.
The award is presented annually by...
What do up to 60% of cancer survivors have in common? Answer: some type of long-term sexual dysfunction. How many cancer survivors seek professional help for sexual problems? Answer: less than 20%. Even when they do seek help, they may not be successful in finding professionals with expertise in...
As researchers continue to integrate neuroscientific findings on how music impacts the human brain, we may see more studies examining biomechanisms in music therapy as well as new situations in which music therapy can play a role in the care of patients with cancer.!-->!-->—...
We were shocked to find only 5% of patients responded correctly to all four questions, which would imply they had sufficient knowledge about their illness to make informed decisions about their care.— Holly Prigerson, PhD
A new study1 showing that just 1 in 20...!-->!-->
Stacey Ann Carter, MD
Stacey Ann Carter, MD, has joined the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine and the Department of Surgery as Assistant Professor. Dr. Carter joins...!-->!-->
Allison Aggon, DO
Allison Aggon, DO, has joined the Department of Surgical Oncology at Fox Chase Cancer Center, focusing on breast surgery. Dr. Aggon comes to Fox Chase from Crozer-Keystone Health System-Delaware County, where she has practiced as a breast surgeon and served as Medical...!-->!-->
This summer, ASCO continued its active involvement in Vice President Joe Biden’s Cancer Moonshot Initiative. ASCO joined the Vice President at the formal launch of the moonshot earlier this year, and since then, has discussed research and policy proposals to advance discovery in cancer treatment...
This summer, ASCO members continued their efforts to advocate for key issues that are critical to cancer care. ASCO members are uniquely qualified to communicate with Congress about effective policies for the treatment of patients with cancer and the research that drives scientific breakthroughs....
Be sure to check out Cancer.Net’s ASCO Answers fact sheets on a variety of topics, including tests and procedures, types of treatment, side effects, and more than 25 cancer types. These one-page (front and back) introductions include an overview, illustrations, terms to know, and questions to ask...
Significant advances in cancer care and treatment have led to a steady increase in survivorship—currently, more than 15.5 million cancer survivors are living in the United States. This number is only expected to grow, with an estimate of more than 20 million American cancer survivors in 2026.1 A...
On August 16, the Journal of Oncology Practice (JOP) published a joint guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine (AAHPM) regarding high-quality palliative care as delivered directly by medical oncology practices themselves.
ASCO has long recommended...
There are a lot more survivors of childhood cancer than there used to be, and that alone is amazing. But now we need to study these patients long-term.— Karen Effinger, MD, MS
When it comes to pediatric cancer, there are so many signs of hope, starting with the fact...!-->!-->
Patricia LoRusso, DO
Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Director of Innovative Medicine at Yale Cancer Center, has been named Chair of the Women in Cancer Research (WICR) Council of the American Association for Cancer Research (AACR).
WICR is a...!-->!-->
Jeff Allen, PhD
Friends of Cancer Research (Friends) has announced that its Executive Director, Jeff Allen, PhD, will assume the role of President and CEO of the organization. Friends’ founder, Ellen Sigal, PhD, will continue with the organization as Board Chair. Dr. Allen will become the ...!-->!-->
Ainel Sewell, MD
Ainel Sewell, MD, has been named the Medical Director of the Breast Care Center at Houston Methodist Willowbrook Hospital. Dr. Sewell is a board-certified radiologist specializing in breast imaging.
“Being asked to lead the breast care center at Houston Methodist...!-->!-->
Bassel F. El-Rayes, MD
Bassel F. El-Rayes, MD, Associate Director of Clinical Research at Winship Cancer Institute of Emory University, was selected to hold the John Kauffman Family Professorship for Pancreatic Cancer Research. The new position was created to support an outstanding leader...!-->!-->
The U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor acute...
Once clinicians know how adolescents and young adults are being affected by their cancer diagnosis, they can develop appropriate interventions to address their specific concerns.— Brad Zebrack, PhD, MSW, MPH, FAPOS
Studies show that adolescent and young adult cancer...!-->!-->
Robert B. Livingston, MD
Over the past couple of decades, chemoradiation for several cancers, such as lung and breast, has advanced in efficacy and side-effect tolerance, prolonging survival and quality of life for patients. One of the pioneers in chemoradiation, Robert B. Livingston, MD,...!-->!-->
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on acute lymphoblastic leukemia. These studies are researching combination chemotherapy; immunotherapies; neuropathic pain prevention; and medication adherence in pediatric...
On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the...
William G. Kaelin,
Peter J. Ratcliffe, MD, FRCP, FMedSci, FRS
Gregg L. Semenza, MD, PhD
Ralf F.W. Bartenschlager, PhD
Charles M. Rice,
Michael J. Sofia, PhD
Bruce M. Alberts, PhD
The Albert and Mary Lasker Foundation has...!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->
The Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group has received federal approval to add a quality-of-life research study, Communication and Education in Tumor Profiling (EAQ152), or COMET, to the NCI-MATCH (EAY131) trial, which is ...
Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s...
Title: The Ultimate Guide to Ovarian Cancer, 2nd edition
Author: Benedict B. Benigno, MD; edited by Beryl Manning-Geist, MD
Publisher: Sherryben Publishing House
E-book release date: June 27, 2016
Price: $7.59, e-book, 252 pages
There have been numerous books...!-->!-->
Michael Maitland, MD, PhD
Inova Health System is pleased to welcome Michael Maitland, MD, PhD, where he will serve as the new Director of Therapeutics for the Inova Center for Personalized Health and as Associate Director of Cancer Therapeutics for the Inova Schar Cancer Institute.
More than being interested in what I have to say, cancer survivors I meet are just happy to see someone who has survived the disease for more than 70 years, and I’m grateful to be a beacon of light for them.— Linda McDonald
Even though I was just 3 years old when my...!-->!-->
Emily L. Sedgwick, MD
Emily L. Sedgwick, MD, Associate Professor of Breast Imaging in the Lester and Sue Smith Breast Center, part of the National Cancer Institute–designated Dan L. Duncan Comprehensive Cancer Center, has been named the 2016 recipient of the Ben and Margaret Love...!-->!-->
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment: A Photographic History,” by Stanley B. Burns, MD, FACS. The photograph below, courtesy of Stanley B. Burns, MD, and The Burns Archive, is...
International Cancer Imaging Society Meeting and 16th Annual Teaching Course
October 3-5 • Glasgow, Scotland
For more information:
9th International Workshop on Waldenstrom’s Macroglobulinemia & Symposia on Multiple Myeloma
Updated Outcomes, Impact of Age in Multiple Myeloma
As reported by Hulin et al in the Journal of Clinical Oncology, the updated findings in the phase III FIRST trial continue to show improved progression-free and overall survival with continuous lenalidomide (Revlimid) plus low-dose dexamethasone...
According to a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...
The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. Sebastian Theurich, MD, of the Center for Integrated Oncology at the University Hospital of Cologne in Germany, and colleagues...
As reported by Ascierto et al in The Lancet Oncology, longer-term follow-up in the pivotal phase III coBRIM trial confirmed the benefit of adding cobimetinib to vemurafenib (Zelboraf) in first-line treatment of BRAF V600–mutant unresectable stage IIIC or IV melanoma. Grant A. McArthur, FRACP, of...
Our work is often described as building and training molecular spies—molecules that will enter a cell or organism and report back to us what the conditions are, what’s going on with the biochemistry, while the cell is still alive.— Roger Y. Tsien, PhD
In 2008, Roger Y....!-->!-->
Saul J. Sharkis, PhD
Saul J. Sharkis, PhD, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died on September 4. He was 72.
Dr. Sharkis was Professor of Oncology at the Johns Hopkins University School...!-->!-->
While a previous study suggested an association, our results show no connection between vasectomies and overall risk of prostate cancer, or of dying from prostate cancer, and should provide some reassurance to men considering vasectomy.— Eric J. Jacobs, PhD
In a new...!-->!-->